Cerus Funding & Investors
Cerus Corporation develops systems designed to enhance the safety of blood transfusions. The Company's systems inactivate pathogens in blood components and inactivate white blood cells, which are responsible for a variety of adverse transfusion reactions. Cerus' platform technologies prevent viral, bacterial, and cellular replication.
cerus.comTotal Amount Raised: $235,800,000
Cerus Funding Rounds
Post Ipo Equity
$63,300,000
Grant
$15,000,000
Post Ipo Equity
$57,500,000
Post Ipo Equity
$70,000,000
Post Ipo Debt
$30,000,000
Post Ipo Debt Investors
Oxford FinancePost Ipo Equity
$63,300,000
Grant
$15,000,000
Post Ipo Equity
$57,500,000
Post Ipo Equity
$70,000,000
Post Ipo Debt
$30,000,000
Post Ipo Debt Investors
Oxford Finance
Funding info provided by Diffbot.